Bicycle Therapeutics, plc’s updated Phase I/II data of BT8009 in urothelial cancer have shown potential for improved drug durability and tolerability when compared to Seagen Inc. /Astellas Pharma, Inc.’s standard-of-care Padcev, rousing optimism for the firm’s unique approach.
Early Data For Bicycle’s Nectin-4 Asset Shows Promising Duration In Urothelial Cancer
Analysts Cautiously Optimistic
The UK-headquartered biotech’s peptide-toxin conjugate showed a prolonged duration of response in advanced urothelial cancer patients in an early-stage trial compared with current standard of care, raising hopes for a differentiated profile.
More from Clinical Trials
More from R&D
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.